Alx Oncology Valuation
| ALXO Stock | USD 1.41 0.12 9.30% |
Based on Macroaxis valuation methodology, the firm appears to be fairly valued. Alx Oncology Holdings shows a prevailing Real Value of $1.28 per share. The current price of the firm is $1.41. Our model approximates the value of Alx Oncology Holdings from analyzing the firm fundamentals such as Shares Owned By Insiders of 1.91 %, return on equity of -0.99, and Current Valuation of (70.7 M) as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Alx Oncology's valuation include:
Price Book 0.4973 | Enterprise Value -70.7 M | Enterprise Value Ebitda (2.35) | Price Sales 5.9 K | Enterprise Value Revenue 4.3 K |
Fairly Valued
Today
Please note that Alx Oncology's price fluctuation is dangerous at this time. Calculation of the real value of Alx Oncology Holdings is based on 3 months time horizon. Increasing Alx Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Alx Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Alx Stock. However, Alx Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.41 | Real 1.28 | Target 17.07 | Hype 1.29 | Naive 1.09 |
The intrinsic value of Alx Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Alx Oncology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Alx Oncology Holdings helps investors to forecast how Alx stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Alx Oncology more accurately as focusing exclusively on Alx Oncology's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Alx Oncology's intrinsic value based on its ongoing forecasts of Alx Oncology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Alx Oncology's closest peers.
Alx Oncology Cash |
|
Alx Valuation Trend
Knowing Alx Oncology's actual value is paramount for traders when making sound investment determinations. Using both Alx Oncology's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Alx Oncology Total Value Analysis
Alx Oncology Holdings is presently anticipated to have valuation of (70.7 M) with market capitalization of 68.04 M, debt of 17.2 M, and cash on hands of 313.37 M. The negative valuation of Alx Oncology may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Alx Oncology fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(70.7 M) | 68.04 M | 17.2 M | 313.37 M |
Alx Oncology Asset Utilization
One of the ways to look at asset utilization of Alx is to check how much profit was generated for every dollar of assets it reports. Alx Oncology Holdings shows a negative utilization of assets of -0.49 percent, losing $0.004925 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Alx Oncology Holdings shows how discouraging it operates for each dollar spent on its assets.Alx Oncology Ownership Allocation
Alx Oncology holds a total of 52.74 Million outstanding shares. The majority of Alx Oncology Holdings outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alx Oncology Holdings to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alx Oncology. Please pay attention to any change in the institutional holdings of Alx Oncology Holdings as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Alx Oncology Profitability Analysis
Net Loss for the year was (160.81 M) with profit before overhead, payroll, taxes, and interest of 107 K.About Alx Oncology Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Alx Oncology Holdings. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Alx Oncology Holdings based exclusively on its fundamental and basic technical indicators. By analyzing Alx Oncology's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Alx Oncology's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Alx Oncology. We calculate exposure to Alx Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Alx Oncology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -836 K | -794.2 K | |
| Pretax Profit Margin | (44.27) | (42.05) | |
| Operating Profit Margin | (42.48) | (40.36) | |
| Net Loss | (44.50) | (42.28) | |
| Gross Profit Margin | 0.08 | 0.07 |
Alx Oncology Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 43 M |
Alx Oncology Current Valuation Indicators
Alx Oncology's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Alx Oncology's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Alx Oncology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Alx Oncology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Alx Oncology's worth.When determining whether Alx Oncology Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alx Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alx Oncology Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alx Oncology Holdings Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.97) | Quarterly Revenue Growth (1.00) | Return On Assets (0.49) | Return On Equity (0.99) |
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.